The growing resistance to antimicrobial drugs represents one of the most urgent challenges in global healthcare today.
According to the World Health Organization (WHO) and the U.S. Centers for Disease Control and Prevention (CDC), resistance to both antibiotics and antifungals is driving a steep rise in morbidity, mortality, and healthcare costs worldwide.

Despite this growing threat, few new drug classes have been developed in recent decades, leaving clinicians with limited treatment options — particularly for high-risk, immunocompromised patients.